Hims (HIMS) is predicted to not exceed earnings expectations for the reported quarter (around Nov 3rd, 2025), and its future guidance is expected to not be better.
"It came in lower than what was expected. I wouldn't expect anything more this quarter. Um especially with with guidance of how medicine and these treatments are supposed to be cheaper under the Trump administration. I don't understand how guidance can in any way be better for him. Just my opinion, just my thoughts."